Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for ARO-APOC3, the company’s investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with hypertriglyceridemia.

Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Pasadena. CA | Posted on March 2nd, 2021

Javier San Martin, M.D., chief medical officer at Arrowhead, said: “There is a clear need for new therapies that can reduce triglycerides across multiple patient populations, including those with the most severe elevations that can lead to recurrent bouts of pancreatitis. In the initial clinical study of ARO-APOC3, which we presented at the American Heart Association meeting last fall, triglycerides were lowered by up to 92% after just two doses. Based on these highly promising results, we intend to conduct Phase 2b and Phase 3 clinical studies across a wide spectrum of patient populations, pending review by regulators.”

Following the FDA’s review of the IND, the company intends to initiate a Phase 2b dose-finding clinical study (ARO-APOC3-2001) in patients with severe hypertriglyceridemia (sHTG). Additional clinical studies planned in 2021 include a Phase 2b dose-finding clinical study in patients with mixed dyslipidemia and a Phase 3 clinical study in patients with familial chylomicronemia syndrome (FCS).

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Media:
LifeSci Communications, LLC
Josephine Belluardo, Ph.D.
646-751-4361

www.lifescicommunications.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Antibody binding-site conserved across COVID-19 virus variants: The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants April 9th, 2021

Discovery could help lengthen lifespan of electronic devices: The research could lead to electronics being designed with better endurance April 9th, 2021

Graphene: Everything under control: Research team demonstrates control mechanism for quantum material April 9th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

Govt.-Legislation/Regulation/Funding/Policy

Better solutions for making hydrogen may lie just at the surface April 9th, 2021

Antibody binding-site conserved across COVID-19 virus variants: The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants April 9th, 2021

3D design leads to first stable and strong self-assembling 1D nanographene wires April 6th, 2021

Qubits comprised of holes could be the trick to build faster, larger quantum computers: Electron holes could be the solution to operational speed/coherence trade-off April 2nd, 2021

Possible Futures

Antibody binding-site conserved across COVID-19 virus variants: The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants April 9th, 2021

Discovery could help lengthen lifespan of electronic devices: The research could lead to electronics being designed with better endurance April 9th, 2021

Graphene: Everything under control: Research team demonstrates control mechanism for quantum material April 9th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

Nanomedicine

Antibody binding-site conserved across COVID-19 virus variants: The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants April 9th, 2021

Discovery could help lengthen lifespan of electronic devices: The research could lead to electronics being designed with better endurance April 9th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

A new agent for the brain diseases: mRNA April 9th, 2021

Announcements

Discovery could help lengthen lifespan of electronic devices: The research could lead to electronics being designed with better endurance April 9th, 2021

Graphene: Everything under control: Research team demonstrates control mechanism for quantum material April 9th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

A new agent for the brain diseases: mRNA April 9th, 2021

Nanobiotechnology

Antibody binding-site conserved across COVID-19 virus variants: The structural revelation could have implications as a therapeutic target in all SARS-CoV-2 variants April 9th, 2021

Energy transmission by gold nanoparticles coupled to DNA structures April 9th, 2021

A new agent for the brain diseases: mRNA April 9th, 2021

DNA--Metal double helix: Single-stranded DNA as supramolecular template for highly organized palladium nanowires March 26th, 2021

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project